Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-03-18 Sale | 2024-03-20 4:38 pm | UroGen Pharma Ltd. | URGN | Schoenberg Mark Chief Medical Officer | 12,000 | $14.05 | $168,600 | 139,437 (Direct) | View |
| 2024-02-01 Sale(A) | 2024-02-05 9:16 pm | UroGen Pharma Ltd. | URGN | Smith Jason Drew General Counsel | 4,993 | $15.78 | $78,790 | 23,414 (Direct) | View |
| 2024-02-01 Sale(A) | 2024-02-05 9:15 pm | UroGen Pharma Ltd. | URGN | Schoenberg Mark Chief Medical Officer | 3,789 | $15.78 | $59,790 | 151,437 (Direct) | View |
| 2024-01-31 Sale | 2024-02-02 7:12 pm | UroGen Pharma Ltd. | URGN | Smith Jason Drew General Counsel | 4,993 | $15.74 | $78,590 | 55,748 (Direct) | View |
| 2024-01-31 Sale | 2024-02-02 7:07 pm | UroGen Pharma Ltd. | URGN | Schoenberg Mark Chief Medical Officer | 3,789 | $15.74 | $59,639 | 169,438 (Direct) | View |
| 2023-08-31 Sale | 2023-09-05 4:28 pm | UroGen Pharma Ltd. | URGN | Smith Jason Drew General Counsel | 3,800 | $18.01 | $68,438 | 18,407 (Direct) | View |
| 2023-01-31 Sale | 2023-02-02 1:04 pm | UroGen Pharma Ltd. | URGN | Smith Jason Drew General Counsel | 1,636 | $10.12 | $16,556 | 79,707 (Direct) | View |
| 2023-01-31 Sale | 2023-02-02 1:02 pm | UroGen Pharma Ltd. | URGN | Schoenberg Mark Chief Medical Officer | 1,900 | $10.12 | $19,228 | 193,227 (Direct) | View |
| 2022-10-31 Sale | 2022-11-02 4:31 pm | UroGen Pharma Ltd. | URGN | Schoenberg Mark Chief Medical Officer | 258 | $11.85 | $3,057 | 24,450 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-01-31 Exercise(A) | 2024-02-12 5:47 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Kim Dong Chief Financial Officer | 3,333 | $0 | 35,253 (Direct) | View |
| 2022-03-25 Option Award(A) | 2024-02-12 5:43 pm | N/A 2032-03-25 | UroGen Pharma Ltd. | URGN | Kim Dong Chief Financial Officer | 20,000 | $0 | 20,000 (Direct) | View |
| 2024-01-31 Exercise | 2024-02-02 7:12 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Smith Jason Drew General Counsel | 10,000 | $0 | 55,748 (Direct) | View |
| 2024-01-31 Option Award | 2024-02-02 7:12 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Smith Jason Drew General Counsel | 16,500 | $0 | 55,748 (Direct) | View |
| 2024-01-31 Exercise | 2024-02-02 7:07 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Schoenberg Mark Chief Medical Officer | 6,666 | $0 | 169,438 (Direct) | View |
| 2024-01-31 Option Award | 2024-02-02 7:07 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Schoenberg Mark Chief Medical Officer | 10,000 | $0 | 169,438 (Direct) | View |
| 2024-01-31 Exercise | 2024-02-02 7:05 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Kim Dong Chief Financial Officer | 3,333 | $0 | 45,252 (Direct) | View |
| 2024-01-31 Option Award | 2024-02-02 7:05 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Kim Dong Chief Financial Officer | 12,000 | $0 | 45,252 (Direct) | View |
| 2024-01-31 Option Award | 2024-02-02 7:04 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Barrett Elizabeth A. Chief Executive Officer | 87,615 | $0 | 87,615 (Direct) | View |
| 2023-09-07 Option Award | 2023-09-08 3:43 pm | N/A 2033-09-07 | UroGen Pharma Ltd. | URGN | Belldegrun Arie Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-09-07 Option Award | 2023-09-08 3:43 pm | N/A 2033-09-07 | UroGen Pharma Ltd. | URGN | BUTITTA CYNTHIA M Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-09-07 Option Award | 2023-09-08 3:42 pm | N/A 2033-09-07 | UroGen Pharma Ltd. | URGN | Cohen Fred E Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-09-07 Option Award | 2023-09-08 3:42 pm | N/A 2033-09-07 | UroGen Pharma Ltd. | URGN | Wildman Daniel George Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-09-07 Option Award | 2023-09-08 3:42 pm | N/A 2033-09-07 | UroGen Pharma Ltd. | URGN | Holden Stuart Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-09-07 Option Award | 2023-09-08 3:41 pm | N/A 2033-09-07 | UroGen Pharma Ltd. | URGN | Robinson James A. Jr. Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-09-07 Option Award | 2023-09-08 3:41 pm | N/A 2033-09-07 | UroGen Pharma Ltd. | URGN | WEN LEANA Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-09-07 Option Award | 2023-09-08 3:41 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Smith Jason Drew General Counsel | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-09-07 Option Award | 2023-09-08 3:41 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Kim Dong Chief Financial Officer | 7,500 | $0 | 7,500 (Direct) | View |
| 2023-09-07 Option Award | 2023-09-08 3:40 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Schoenberg Mark Chief Medical Officer | 5,000 | $0 | 5,000 (Direct) | View |
| 2023-08-31 Exercise | 2023-09-05 4:28 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Smith Jason Drew General Counsel | 8,334 | $0 | 18,407 (Direct) | View |
| 2023-07-26 Option Award | 2023-07-28 6:06 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Cohen Fred E Director | 69,339 | $9.54 | 69,339 (Indirect) | View |
| 2023-07-25 Option Award(A) | 2023-07-28 6:05 pm | N/A 2033-07-25 | UroGen Pharma Ltd. | URGN | Robinson James A. Jr. Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2023-07-25 Option Award | 2023-07-27 4:30 pm | N/A 2033-07-25 | UroGen Pharma Ltd. | URGN | Robinson James A. Jr. Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2023-06-08 Option Award | 2023-06-09 3:26 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Schoenberg Mark Chief Medical Officer | 30,000 | $0 | 30,000 (Direct) | View |
| 2022-06-06 Exercise(A) | 2023-02-28 12:29 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $5 | 1,434,958 (Indirect) | View |
| 2022-06-06 Exercise(A) | 2023-02-28 12:29 pm | 2015-09-01 2022-09-01 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $0 | 1,434,958 (Indirect) | View |
| 2022-10-21 Exercise(A) | 2023-02-28 12:23 pm | 2018-12-27 2022-12-27 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 47,999 | $0 | 1,485,168 (Indirect) | View |
| 2022-10-21 Exercise(A) | 2023-02-28 12:23 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 47,999 | $5.94 | 1,485,168 (Indirect) | View |
| 2022-06-16 Exercise | 2023-02-28 12:21 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 2,211 | $5 | 1,437,169 (Indirect) | View |
| 2022-06-16 Exercise | 2023-02-28 12:21 pm | 2015-09-01 2022-09-01 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 2,211 | $0 | 1,437,169 (Indirect) | View |
| 2023-01-31 Exercise | 2023-02-02 3:40 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Barrett Elizabeth A. Chief Executive Officer | 18,333 | $0 | 640,025 (Direct) | View |
| 2023-01-31 Option Award | 2023-02-02 3:40 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Barrett Elizabeth A. Chief Executive Officer | 300,000 | $0 | 640,025 (Direct) | View |
| 2023-01-31 Option Award | 2023-02-02 1:05 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Kim Dong Chief Financial Officer | 48,000 | $0 | 48,000 (Direct) | View |
| 2023-01-31 Exercise | 2023-02-02 1:04 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Smith Jason Drew General Counsel | 3,333 | $0 | 79,707 (Direct) | View |
| 2023-01-31 Option Award | 2023-02-02 1:04 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Smith Jason Drew General Counsel | 60,000 | $0 | 79,707 (Direct) | View |
| 2023-01-31 Exercise | 2023-02-02 1:02 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Schoenberg Mark Chief Medical Officer | 3,833 | $0 | 193,227 (Direct) | View |
| 2023-01-31 Option Award | 2023-02-02 1:02 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Schoenberg Mark Chief Medical Officer | 40,000 | $0 | 193,227 (Direct) | View |
| 2023-01-20 Exercise | 2023-01-23 7:10 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Schoenberg Mark Chief Medical Officer | 122,677 | $5 | 146,627 (Direct) | View |
| 2023-01-20 Exercise | 2023-01-23 7:10 pm | 2019-01-20 2023-01-20 | UroGen Pharma Ltd. | URGN | Schoenberg Mark Chief Medical Officer | 122,677 | $0 | 146,627 (Direct) | View |
| 2022-11-08 Option Award | 2022-11-09 5:57 pm | N/A 2032-11-08 | UroGen Pharma Ltd. | URGN | Wildman Daniel George Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2022-10-31 Exercise | 2022-11-02 4:31 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Schoenberg Mark Chief Medical Officer | 500 | $0 | 24,450 (Direct) | View |
| 2022-10-21 Exercise | 2022-10-25 4:57 pm | 2018-12-27 2022-12-27 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 47,999 | $0 | 1,481,927 (Indirect) | View |
| 2022-10-21 Exercise | 2022-10-25 4:57 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 47,999 | $5.94 | 1,481,927 (Indirect) | View |
| 2022-09-14 Exercise | 2022-09-16 3:13 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Belldegrun Arie Director | 160,000 | $5 | 408,693 (Direct) | View |
| 2022-09-14 Exercise | 2022-09-16 3:13 pm | 2019-10-07 2022-10-07 | UroGen Pharma Ltd. | URGN | Belldegrun Arie Director | 160,000 | $0 | 408,693 (Direct) | View |
| 2022-09-08 Option Award | 2022-09-12 08:28 am | N/A 2032-09-08 | UroGen Pharma Ltd. | URGN | WEN LEANA Director | 20,000 | $0 | 20,000 (Direct) | View |